+86 137 2013 4139
+86 137 2013 4139
| CAS: | 1513883-39-0 | Cat No: | JKN00644 | Purity: | 98% |
Note: All products of the company are for scientific research only, and do not provide products and services for any individual
Product Description
| CAS | 1513883-39-0 | Cat No | JKN00644 | |
| Name | Deuruxolitinib | |||
| Synonyms | Deuruxolitinib | |||
| Smiles | [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H] | |||
| Chemical Name | (3R)-3-(2,2,3,3,4,4,5,5-octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile | |||
| Formula | C17H18N6 | MWt | 314.41 | |
| Purity | 98% | Storage | Store at 4--8℃ | |
| Description | Deuruxolitinib is a deuterated form of [ruxolitinib] that selectively inhibits Janus kinases (JAK) JAK1 and JAK2. Deuteration allows the drug to circumvent extensive oxidative metabolism around the cyclopentyl ring, which increases the duration of the pharmacological activity of deuruxolitinib. On July 26, 2024, deuruxolitinib was approved by the FDA for the treatment of severe alopecia areata. Alopecia areata is an autoimmune condition that attacks the hair follicles and leads to unpredictable hair loss in the scalp and other areas of the body. The Janus kinase (JAK) signal transducer and activator of transcription (STAT) pathway has been implicated in the pathophysiology of alopecia areata, as it regulates the expression of inflammatory mediators. Deuruxolitinib works to block the inflammatory responses caused by JAKs. | |||
Product Documents
Menu
Contact Us
Tel: +86 137 2013 4139
E-mail: orders@jknbiochem.com
Add.:Room 2120, Office Building 2, No.1 Baisha Fifth Road, Hongshan District, Wuhan City, Hubei Province, China
Get In Touch
Get In Touch
